截至2025年8月8日收盘，百利天恒（688506）报收于295.45元，较上周的305.18元下跌3.19%。本周， 百利天恒8月6日盘中最高价报312.98元。8月4日盘中最低价报289.0元。百利天恒当前最新总市值 1184.75亿元，在化学制药板块市值排名3/150，在两市A股市值排名127/5151。 本周关注点 四川百利天恒药业股份有限公司于2025年8月7日收到中国证券监督管理委员会出具的批复，同意公司向 特定对象发行股票的注册申请。批复要求公司严格按照报送上海证券交易所的申报文件和发行方案实 施，且该批复自同意注册之日起12个月内有效。在此期间，若公司发生重大事项，应及时报告上海证券 交易所并按有关规定处理。公司董事会将在规定期限内办理本次向特定对象发行股票的相关事项，并及 时履行信息披露义务。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 公司公告汇总：百利天恒向特定对象发行股票申请获得中国证监会同意注册批复 公司公告汇总 ...

Group 1 - The core point of the news is that China Europe Fund announced a limit on daily subscriptions for the China Europe Medical Innovation Fund to 100,000 yuan starting from August 11, 2025, to ensure stable fund operations and protect the interests of fund shareholders [1][2][3] - The China Europe Medical Innovation Fund, managed by fund manager Ge Lan, was established in February 2019 and primarily invests in stocks related to medical innovation [3][4] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [5][6] Group 2 - The top ten holdings of the fund include companies such as Sanofi Pharmaceutical, Keren Biotechnology, and Kangfang Biotech, with the largest holding, Sanofi Pharmaceutical, showing a year-to-date increase of nearly 400% [4][6] - The fund's unit net value has been rising, reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug sector, with expectations for global collaboration and important clinical data disclosures, as well as ongoing domestic policy support for high-quality drug development [8]

Group 1 - The core announcement from China Europe Fund is the suspension of large subscriptions, conversions, and regular investment for the China Europe Medical Innovation Equity Fund starting from August 11, 2025, with a daily limit of 100,000 yuan per account to ensure fund stability and protect the interests of fund shareholders [1][3][10] - The China Europe Medical Innovation Fund, established in February 2019 and managed by fund manager Ge Lan, primarily invests in stocks related to the medical innovation sector, aiming to achieve returns that exceed the performance benchmark while strictly controlling investment risks [1][3][5] - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with major investments in healthcare and manufacturing sectors, accounting for 46.41% and 41.99% of the total assets, respectively [4][5] Group 2 - The top ten holdings of the fund include companies such as 3SBio, Kelun-Biotech, and Kangfang Biotech, with the largest holding, 3SBio, showing a remarkable increase of nearly 400% this year [4][6][8] - The fund's unit net value has been on the rise, reaching 1.6874 yuan, significantly up from below 0.9 yuan a year ago, reflecting the rebound in the innovative drug sector [7][8] - The fund's outlook for the third quarter highlights optimism in the innovative drug field, with expectations for global cooperation and important clinical data disclosures, alongside supportive domestic policies for high-quality development in innovative drugs [8]

Core Viewpoint - The article discusses the recent announcement by China Europe Fund regarding the limitation on large subscriptions for the China Europe Medical Innovation Fund, aimed at ensuring stable operations and protecting the interests of fund shareholders [1][3]. Fund Management and Performance - The China Europe Medical Innovation Fund, managed by fund manager Ge Lan, was established in February 2019 and primarily invests in stocks related to medical innovation [3][5]. - As of mid-2023, the fund's total net asset value exceeded 8.2 billion yuan, with the top ten holdings including companies like Sanofi Pharmaceutical and WuXi AppTec [4][5]. - The fund's top ten stocks have all seen significant increases this year, with the largest being Sanofi Pharmaceutical, which has risen nearly 400% [5][6]. Investment Strategy and Market Outlook - The fund focuses on actively managing asset allocation while strictly controlling investment risks, aiming to achieve returns that exceed performance benchmarks [3][5]. - The outlook for the third quarter highlights optimism in the innovative drug sector, with expectations for global collaboration and important clinical data disclosures [8]. - The fund anticipates continued growth in the consumer healthcare sector, particularly in aesthetic medicine and home medical devices, driven by rising health awareness among residents [8]. Recent Developments - On August 9, 2023, the fund announced a daily subscription limit of 100,000 yuan per account, effective from August 11, 2023, to manage large inflows and maintain stability [1][3]. - The fund's unit net value has been on the rise, recently reaching 1.6874 yuan, compared to a low of below 0.9 yuan a year ago [7].

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan, accounting for more than 21% of the total [1] Salary Distribution - The average annual salary for company secretaries in the chemical preparation sector of A-shares is 914,800 yuan [2] - Salary distribution among company secretaries shows that 33% earn below 500,000 yuan, 37% earn between 500,000 and 1 million yuan, 27% earn between 1 million and 2 million yuan, and 3% earn above 2 million yuan [2] - Four company secretaries earn over 3 million yuan, with salaries of 5.2065 million yuan, 4.2101 million yuan, 3.3837 million yuan, and 3 million yuan respectively [2] Age and Educational Background - The age distribution of company secretaries indicates that those aged 40-50 constitute 46%, while those over 50 account for 21%, and those aged 40 or below make up 33% [1] - The educational background shows that 7% have an associate degree, 37% hold a bachelor's degree, 50% possess a master's degree, and 6% have a doctoral degree [2] - Among the company secretaries, only six hold a doctoral degree, with one being the only full-time secretary in the industry [2] Salary Changes - The largest salary decrease was observed for Wang Qin from ST Tian Sheng, with a year-on-year decline of 81.28% [2] - The highest salary increase was recorded for Chen Bo from Huadong Medicine, with a year-on-year increase of 308.81% [2]

专题：专题|2024年度A股董秘数据报告：1144位董秘年薪超百万 占比超21% 董秘作为连接投资者与上市公司的"桥梁"，在上市公司资本运作中发挥着关键作用。新浪财经《2024年 度A股董秘数据报告》显示，2024年A股上市公司董秘薪酬合计达40.86亿元，平均年薪75.43万元。 分行业来看，统计数据显示，剔除未任职2024年全年董秘数据后，A股共有110家上市化学制剂公司， 其聘任总体情况如下（部分统计口径剔除无效数据）。 从董秘的年龄分布来看，40岁-50岁董秘是市场的中坚力量，占比共计达到46%；50岁以上的董秘占比 为21%；小于或等于40岁的董秘群体占比为33%。其中，目前仍任职的最年轻的男上市公司董秘年龄31 岁，为莎普爱思的黄明雄；最年轻的女董秘年龄为33岁，为百利天恒的陈英格。 从董秘的学历分布看，拥有专科、本科、硕士、博士学历的董秘占比分别为7%、37%、50%、6%。其 中，获得博士学历的董秘共6人，分别为舒泰神的于茂荣、人福医药（维权）的李前伦、灵康药业（维 权）的隋国平、海正药业的沈锡飞、益方生物-U的江岳恒、健友股份的黄锡伟。其中，海正药业的沈 锡飞为行业唯一一个拥有博士学历的专职 ...

Group 1 - The core stock price of Baili Tianheng as of August 7, 2025, is 298.41 yuan, with a decrease of 7.78 yuan, representing a decline of 2.54% [1] - The trading volume on the same day was 7278 hands, with a total transaction amount of 220 million yuan [1] - Baili Tianheng focuses on innovative drug research and development, with its main business covering chemical drug formulations and traditional Chinese medicine research, production, and sales [1] Group 2 - On the evening of August 7, Baili Tianheng announced that its application for the issuance of stocks to specific targets has been approved by the China Securities Regulatory Commission [1] - The total amount of funds to be raised in this issuance is not expected to exceed 3.764 billion yuan, which will be entirely used for innovative drug research and development projects [1] - The net outflow of main funds for Baili Tianheng on that day was 1.6973 million yuan, with a cumulative net outflow of 4.6502 million yuan over the past five days [1]

简历显示：郑宁先生:中国,研究生、硕士。曾任泰康资产管理有限责任公司股票研究经理、高级股票研 究经理;中庚基金管理有限公司研究员、高级研究员(医药组组长)。2022年加入中银基金管理有限公司。 2022年7月1日担任中银创新医疗混合型证券投资基金基金经理。2022年10月13日担任中银医疗保健灵活 配置混合型证券投资基金基金经理。2023年2月28日任中银大健康股票型证券投资基金基金经理。 来源：金融界 金融界2025年8月7日消息，中银创新医疗混合A(007718) 最新净值2.1723元，下跌3.54%。该基金近1个 月收益率12.66%，同类排名684|4457；近6个月收益率78.76%，同类排名23|4316；今年来收益率 80.53%，同类排名29|4287。 中银创新医疗混合A股票持仓前十占比合计62.83%，分别为：信达生物（8.33%）、科伦博泰生 （8.15%）、恒瑞医药（8.08%）、康方生物（8.07%）、新诺威（6.13%）、百利天恒（5.99%）、百济 神州-U（5.97%）、翰森制药（4.15%）、荣昌生物（4.05%）、康诺亚-B（3.91%）。 公开资料显示，中银创新医疗混合 ...

智通财经APP讯，百利天恒(688506.SH)发布公告，公司于2025年8月7日收到中国证券监督管理委员会 出具的《关于同意四川百利天恒药业股份有限公司向特定对象发行股票注册的批复》(证监许可 〔2025〕1641号)，同意公司向特定对象发行股票的注册申请。 ...

证券代码：688506 证券简称：百利天恒 公告编号：2025-050 四川百利天恒药业股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 四川百利天恒药业股份有限公司（以下简称"公司"）于 2025 年 8 月 7 日 收到中国证券监督管理委员会出具的《关于同意四川百利天恒药业股份有限公司 向特定对象发行股票注册的批复》（证监许可〔2025〕1641 号），批复主要内容 如下： 一、同意你公司向特定对象发行股票的注册申请。 二、你公司本次发行应严格按照报送上海证券交易所的申报文件和发行方案 实施。 三、本批复自同意注册之日起 12 个月内有效。 四、自同意注册之日起至本次发行结束前，你公司如发生重大事项，应及时 报告上海证券交易所并按有关规定处理。 公司董事会将按照上述批复文件和相关法律法规的要求以及公司股东大会 的授权，在规定期限内办理本次向特定对象发行股票的相关事项，并及时履行信 息披露义务，敬请广大投资者注意投资风险。 特此公告。 关于向特定对象发行股票申请获得 中国证券监督管理委员会同意注册批复的公告 ...